Pyzchiva

ustekinumab-ttwe · USTEKINUMAB 45 mg/.5mL · Injection, Solution · Subcutaneous · Cordavis Limited

NDC 83457-0651-01 · 1 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE · BLA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

Matched to CMS's representative package for this drug (NDC 83457-0651-96) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$4,248.50per unit

middle half $4,211.25–$4,330.38 · 1,328 plans · Apr 1, 2026

Est. net of rebatesⓘ

$2,549.10–$3,186.38

brand drug — est. 25-40% rebate off the price at left

Coverage & restrictions

24%of plans cover it

tier 3 · prior auth 100% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$2,075.00

Reported to Texas DSHS · 2026 annual filing · Cordavis Limited

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: BLA761373
TE code: —
Approval date: —
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of ustekinumab-ttwe (Injection, Solution)

Labeler	Strength	First seen	Last seen
Quallent Pharmaceuticals Health LLC	USTEKINUMAB 45 mg/.5mL	Jul 15, 2026	Sep 3, 2026
Cordavis Limited	USTEKINUMAB 90 mg/mL	Jul 15, 2026	Sep 2, 2026
Cordavis Limited	USTEKINUMAB 45 mg/.5mL	Jul 15, 2026	Sep 2, 2026
Patheon Italia S.p.A	USTEKINUMAB 130 mg/26mL	Jul 15, 2026	Sep 2, 2026
Patheon Italia S.p.A	USTEKINUMAB 45 mg/.5mL	Jul 15, 2026	Sep 2, 2026
Patheon Italia S.p.A	USTEKINUMAB 90 mg/mL	Jul 15, 2026	Sep 2, 2026
Quallent Pharmaceuticals Health LLC	USTEKINUMAB 130 mg/26mL	Jul 15, 2026	Sep 2, 2026
Quallent Pharmaceuticals Health LLC	USTEKINUMAB 90 mg/mL	Jul 15, 2026	Sep 2, 2026
Sandoz Inc	USTEKINUMAB 45 mg/.5mL	Jul 15, 2026	Sep 2, 2026
Sandoz Inc	USTEKINUMAB 90 mg/mL	Jul 15, 2026	Sep 2, 2026
Sandoz Inc	USTEKINUMAB 130 mg/26mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Pyzchiva — NDC 83457-0651-01," retrieved September 3, 2026, https://drugdashboards.com/drug/83457065101.

Free to cite with attribution — see how the data is put together.